Eiken Chemical Co., Ltd. (JP:4549)
:4549
Top Page
Eiken Chemical Co., Ltd.
(4549)
Select Model
Select Model
Rating:68Neutral
Price Target:
¥2,978.00
▲(23.72% Upside)
Action:ReiteratedDate:02/25/26
The score is supported primarily by a strong, low-leverage balance sheet and generally stable operating performance, but is held back by declining profitability and weakening free cash flow. Technically, the uptrend is intact, yet extremely overbought momentum raises near-term risk, and valuation (P/E 26.24 with ~1.70% yield) is not especially attractive.
Positive Factors
Strong balance sheet / low leverage
Very low financial leverage and a high equity ratio provide durable financial flexibility. This capital structure reduces refinancing risk, lets the company fund R&D, working capital, or acquisitions internally, and cushions it against reimbursement or demand shocks over months to years.
Negative Factors
Declining profitability metrics
Net margin compression and falling ROE signal weaker returns on sales and equity, limiting internal capital available for reinvestment. Persistently lower profitability could constrain ability to fund growth, maintain R&D intensity, or deliver improving shareholder returns over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet / low leverage
Very low financial leverage and a high equity ratio provide durable financial flexibility. This capital structure reduces refinancing risk, lets the company fund R&D, working capital, or acquisitions internally, and cushions it against reimbursement or demand shocks over months to years.
Read all positive factors
Eiken Chemical Co., Ltd. (4549) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥111.43B
Dividend Yield2.31%
Average Volume (3M)72.32K
Price to Earnings (P/E)26.7
Beta (1Y)0.64
Revenue Growth4.36%
EPS Growth79.43%
CountryJP
Employees757
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)22.51
Shares Outstanding34,541,440
10 Day Avg. Volume81,940
30 Day Avg. Volume72,320
Financial Highlights & Ratios
PEG Ratio-3.65
Price to Book (P/B)1.79
Price to Sales (P/S)1.92
P/FCF Ratio95.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)91.9
Revenue Forecast (FY)¥43.56B
Eiken Chemical Co., Ltd. Business Overview & Revenue Model
Company Description
Eiken Chemical Co., Ltd. manufactures and sells clinical diagnostics and equipment in Japan. The company is involved in developing clinical diagnostic aids to various aspects of contemporary medicine, including biochemical, immunological, serologi...
How the Company Makes Money
Eiken Chemical primarily makes money by selling in vitro diagnostic (IVD) products used by clinical laboratories and healthcare institutions. Its core revenue stream is the sale of diagnostic reagents and test kits consumed in routine and speciali...
Eiken Chemical Co., Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
80
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 41.22B | 40.54B | 40.05B | 43.27B | 43.00B | 38.66B |
| Gross Profit | 16.66B | 16.51B | 16.72B | 20.51B | 20.57B | 18.53B |
| EBITDA | 6.86B | 5.56B | 5.84B | 9.73B | 10.55B | 8.58B |
| Net Income | 2.34B | 2.23B | 2.63B | 5.74B | 6.22B | 5.04B |
Balance Sheet | ||||||
| Total Assets | 59.50B | 62.97B | 62.25B | 66.76B | 63.02B | 56.18B |
| Cash, Cash Equivalents and Short-Term Investments | 4.67B | 9.87B | 16.31B | 18.32B | 16.12B | 9.23B |
| Total Debt | 3.00B | 4.47B | 4.33B | 4.31B | 4.19B | 1.16B |
| Total Liabilities | 17.74B | 19.37B | 16.28B | 17.22B | 17.22B | 14.51B |
| Stockholders Equity | 41.75B | 43.60B | 45.97B | 49.53B | 45.80B | 41.67B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 812.00M | 1.72B | 4.30B | 2.88B | 3.34B |
| Operating Cash Flow | 0.00 | 6.03B | 3.81B | 7.58B | 7.77B | 5.45B |
| Investing Cash Flow | 0.00 | -4.50B | -2.22B | -316.00M | -5.04B | -2.19B |
| Financing Cash Flow | 0.00 | -4.86B | -6.69B | -2.10B | 1.20B | -1.27B |
Eiken Chemical Co., Ltd. Technical Analysis
Positive
2407.00
Price Trends
2826.31
Positive
2611.26
Positive
2436.19
Positive
Market Momentum
121.32
Negative
70.46
Negative
92.80
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4549, the sentiment is Positive. The current price of 2407 is below the 20-day moving average (MA) of 3002.48, below the 50-day MA of 2826.31, and below the 200-day MA of 2436.19, indicating a bullish trend. The MACD of 121.32 indicates Negative momentum. The RSI at 70.46 is Negative, neither overbought nor oversold. The STOCH value of 92.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4549.
Eiken Chemical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥20.38B | 15.12 | ― | 3.02% | -4.36% | -14.92% | |
69 Neutral | ¥35.68B | 10.15 | ― | 2.93% | 6.72% | 20.01% | |
68 Neutral | ¥111.43B | 26.70 | ― | 2.31% | 4.36% | 79.43% | |
65 Neutral | ¥260.93B | 36.37 | ― | 1.92% | 4.31% | 96.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥141.80B | 28.05 | 2.42% | 3.73% | 0.04% | ― |
* Healthcare Sector Average
JP:4549
Eiken Chemical Co., Ltd.
3,380.00
1,390.75
69.91%
JP:6523
PHC Holdings Corp.
1,119.00
280.98
33.53%
JP:6678
Techno Medica Co., Ltd.
2,391.00
782.12
48.61%
JP:6823
Rion Co., Ltd.
2,894.00
895.35
44.80%
JP:6849
Nihon Kohden Corporation
1,563.00
-122.06
-7.24%
Eiken Chemical Co., Ltd. Corporate Events
Eiken Chemical Overhauls Governance With New C-Suite Structure
Feb 26, 2026
Eiken Chemical will introduce a formal C-suite structure on April 1, 2026, creating roles including CEO, COO, CMSO, CTO, CPO, CFO, and CHRO to place domain experts at the center of core business functions. The company expects this governance shift...
Eiken Chemical Posts Strong Profit Surge, Lifts Dividend and Confirms Full-Year Outlook
Jan 30, 2026
Eiken Chemical reported consolidated net sales of ¥31.38 billion for the nine months ended December 31, 2025, up 2.4% year on year, with operating profit rising 5.5% to ¥2.78 billion and profit attributable to owners of parent jumping 75...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.